T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells (original) (raw)
Dendritic cell-based vaccine in advanced melanoma
Emanuela Scarpi
Melanoma Research, 2011
View PDFchevron_right
Cell-based vaccination against melanoma – background, preliminary results, and perspective
Dirk Schadendorf
Journal of Molecular Medicine, 1999
View PDFchevron_right
Transfected human dendritic cells to induce antitumor immunity
Hassan Rahimi
Gene Therapy, 1999
View PDFchevron_right
Targeted Cancer Therapy by Dendritic Cell Vaccine
Minako Abe
Cancer Treatment - Conventional and Innovative Approaches, 2013
View PDFchevron_right
Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells
William Mcbride
Cancer Gene Therapy, 1999
View PDFchevron_right
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
Ji-li Chen
International Journal of Cancer, 2000
View PDFchevron_right
Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein
Javier Carrasco Carrasco
The Journal of Immunology, 2005
View PDFchevron_right
Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination
Mohammad Aghasadeghi
Medical Oncology, 2011
View PDFchevron_right
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Gustav Gaudernack
Oncoimmunology, 2016
View PDFchevron_right
Loading of dendritic cells for immunotherapy
A. Van Nuffel
ISBT Science Series, 2013
View PDFchevron_right
Melanoma and immunotherapy bridge 2015
Angel Rivera
Journal of Translational Medicine, 2016
View PDFchevron_right
Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Markus Frank
2023
View PDFchevron_right
Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Markus Frank
2023
View PDFchevron_right
Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
Cristina SANTANTONIO
Cancer Immunology, Immunotherapy, 2002
View PDFchevron_right
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Gustav Gaudernack
Cancer Gene Therapy, 2005
View PDFchevron_right
Cancer Vaccines and Tumor Immunity
Veronica Preda
2007
View PDFchevron_right
Dendritic cell vaccines in melanoma: From promise to proof?
Danita Schuurhuis, I Jolanda Vries, Gosse Adema, Erik Aarntzen
Critical Reviews in Oncology/Hematology, 2008
View PDFchevron_right
Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model
Kimberly George
Cancer Immunology, Immunotherapy, 2003
View PDFchevron_right
Tumor Antigen Processing and Presentation Depend Critically on Dendritic Cell Type and the Mode of Antigen Delivery
Ian Davis
…, 2005
View PDFchevron_right
Aspects of cancer immunotherapy
Bruce Loveland
Immunology and Cell Biology, 2003
View PDFchevron_right
Development of an RNA loaded dendritic cell (DC) immunotherapy starting from tissue obtained via needle biopsy
Charles Nicolette
European Journal of Cancer, 2016
View PDFchevron_right
Optimization of Production of Anti-Cancer Vaccines Based on Dendritic Cells
Zélia Silva
2015
View PDFchevron_right
Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients
Annemiek Boer
Clinical Cancer Research, 2011
View PDFchevron_right
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
Laura Ridolfi
Journal of Translational Medicine, 2013
View PDFchevron_right
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
G. Adema, Kalijn Bol, Gerty Schreibelt, I Jolanda Vries, Joannes Jacobs, Roel Mus, Erik Aarntzen
Clinical Cancer Research, 2012
View PDFchevron_right
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma
Tam Nguyen
Cancer Immunology Immunotherapy, 2004
View PDFchevron_right
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
Tom Van Oorschot, Mandy W. M. M. Rakt, Joannes Jacobs, I Jolanda Vries, Roel Mus, Nicole Scharenborg, Erik Aarntzen
Oncoimmunology, 2015
View PDFchevron_right
Cancer Immunotherapy: A breakthrough in patient care
Abdallah Badou
Health Sciences, 2022
View PDFchevron_right
Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model
Arezoo Jamali
Cellular Immunology, 2011
View PDFchevron_right